Partnered Discovery of High-quality Antibody Drug Candidates

Transcription

1 Partnered Discovery of High-quality Antibody Drug Candidates COMPANY PRESENTATION SEPTEMBER 2017

2 Corporate Overview A unique source of therapeutic human antibodies with one of the industry's most versatile technology platforms, validated through two products in the clinic Pure partnered-discovery provider High-quality, high-value antibodies based on cutting-edge technology, that integrates antibody screening and optimization platforms Dual offering of natural and engineered libraries, providing both phage and yeast display options Only provider of rapid humanization of rabbit antibodies 2

3 What We Offer to Partners AbCheck s suite of antibody technologies: Naïve Human Mass Humanized AbSieve AbAccel Human Antibody Libraries Selection Optimization Provides partners with various options for the de novo discovery of antibodies against virtually all targets in scfv, IgG or bi-specific formats the optimization of existing antibody-based drug candidates 3

4 Our Current Partner Network - Over 30 Successful Antibody Discovery Projects Undisclosed partners

5 AbCheck s Commitment to Meeting Industry Demands Industry Needs AbCheck s Solution Desire to work in final drug format AbSieve Desire to use in vivo generated antibodies and humanize them consistently Desire to optimize drug-like properties of antibody candidates Mass Humanization AbAccel Desire to identify specific antibodies with high developability potential Naïve Human Libraries 5

6 AbCheck s Unique Offering Genetically and conceptually distinct libraries allow for sequence exclusivity and availability 6

7 AbCheck s Unique Offering AbCheck can provide a seamless and smart transition between phage and yeast display selection strategies 7

8 Case Study: Opportunities in Advancing Therapeutic Areas New therapeutic approaches on the rise that use antibodies or fragments as components Technology platform is particularly well suited to deliver single-chain variable fragments as targeting elements Natural Human Library has delivered highly specific scfv with affinities in the single digit nanomolar range used in initial project Chimeric Antigen Receptor (CAR) 8

9 Case Study: Immune Checkpoints Antibodies targeting Immune Checkpoints are powerful immuno-activators and have shown impressive results in various cancer indications AbCheck has identified anti-checkpoint IgGs with in vivo activity using its AbSieve technology 9

10 AbCheck Corporate Background Leadership with substantial expertise in the biopharmaceutical industry Experience in discovery platforms through Affimed, Celltech, Cosmix, Fresenius, Pieris and Scil Technology AbCheck is a fully-owned subsidiary of Affimed (Nasdaq: AFMD) Validation through several clinical programs AbCheck retains a maximum level of independence No shared labs or location 10

11 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE

12 Unique Antibody Sources, Selection Methods and Optimization Tools Naïve Human Mass Humanized AbSieve AbAccel Human Antibody Libraries Selection Optimization Unique sources of human antibodies through natural, immunized and smartlyengineered libraries Next generation Yeast Display capability Advanced optimization tools 12

13 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE - LIBRARIES

14 The Human Antibody Library Low immunogenicity by nature Largest structural diversity Delivers high affinity and highly specific antibodies without optimizations From healthy donors (not engineered) Used by AbCheck since 2010 with proven and robust performance 15

15 Mass Humanization Co-developed with Distributed Bio, AbCheck gained the exclusive license to the technology in 2015 A novel approach to human antibody discovery Combining the power of in vivo immunization with the best of in vitro engineering and in silico computational optimization Special potential for difficult targets Immunized libraries Computational design In vitro selection 17

16 AbCheck s Mass Humanization Delivers Antibodies That are More Human 18

17 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE SELECTION IN THE FINAL DRUG FORMAT

18 AbSieve Next Generation Yeast Display for Advanced Selection Potential Recommended for selections of IgG and bi-specifics Screening in final drug format IgG (bivalent) Target specific VH/VL pools Yeast Display Bi-specific formats Any other formats AbSieve avoids drop-outs due to reformatting 18

19 Partnered Discovery of High-quality Antibody Drug Candidates TECHNOLOGY SUITE OPTIMIZATION

20 AbAccel High-end Lead Optimization AbCheck has the exclusive license to the technology, co-developed with Distributed Bio Premium optimization method To meet special affinity requirements To improve developability Quality upgrade and final polishing before development Maintains beneficial antibody properties 20

21 AbAccel Optimizes Affinity While Preserving Other Drug-Relevant Properties AbAccel achieved two logs improvement in affinity with optimal species cross-reactivity and thermal stability Complete permutation of 50 CDR positions enabled paratope delineation 21

22 AbCheck Summary One of the most versatile therapeutic antibody platforms that provides a customizable way to your lead candidate Accessible through a pure partnered-discovery model Experts in: antibody discovery lead optimization and humanization Successfully validated platform AbCheck antibodies already in clinical and preclinical development Seeking more partners for drug discovery and novel technology to add further capabilities 22

23 Contact: Volker Lang, PhD General Manager AbCheck